Praxis Precision Medicines, Inc. Profile Avatar - Palmy Investing

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA rec…

Biotechnology
US, Boston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Praxis Precision Medicines, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of PRAX's Analysis
CIK: 1689548 CUSIP: 74006W108 ISIN: US74006W2070 LEI: - UEI: -
Secondary Listings
PRAX has no secondary listings inside our databases.